Quoin Pharmaceuticals Ltd reported positive clinical results from its ongoing study of QRX003 for treating Netherton Syndrome, showing significant skin healing and elimination of itch in a pediatric patient after 6 weeks of treatment, with no adverse events reported. The company plans to start treatment on a second patient soon.